Chen, K.Y.; Popovic, A.; Hsiehchen, D.; Baretti, M.; Griffith, P.; Bista, R.; Baghdadi, A.; Kamel, I.R.; Simon, S.M.; Migler, R.D.;
et al. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers 2022, 14, 5347.
https://doi.org/10.3390/cancers14215347
AMA Style
Chen KY, Popovic A, Hsiehchen D, Baretti M, Griffith P, Bista R, Baghdadi A, Kamel IR, Simon SM, Migler RD,
et al. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers. 2022; 14(21):5347.
https://doi.org/10.3390/cancers14215347
Chicago/Turabian Style
Chen, Krista Y., Aleksandra Popovic, David Hsiehchen, Marina Baretti, Paige Griffith, Ranjan Bista, Azarakhsh Baghdadi, Ihab R. Kamel, Sanford M. Simon, Rachael D. Migler,
and et al. 2022. "Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors" Cancers 14, no. 21: 5347.
https://doi.org/10.3390/cancers14215347
APA Style
Chen, K. Y., Popovic, A., Hsiehchen, D., Baretti, M., Griffith, P., Bista, R., Baghdadi, A., Kamel, I. R., Simon, S. M., Migler, R. D., & Yarchoan, M.
(2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 14(21), 5347.
https://doi.org/10.3390/cancers14215347